DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Phase 2

Recruiting

Conditions: Stage II Renal Cell Cancer
Sarcomatoid Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Drug: Zirconium Zr 89 Girentuximab

First Posted Date: 2024-06-06

Last Posted Date: 2024-08-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 91

Registration Number: NCT06447103

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

Phase 2

Recruiting

Conditions: Abdominopelvic Sarcomas

Interventions: Radiation: Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy

First Posted Date: 2024-05-31

Last Posted Date: 2024-12-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT06436612

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Phase 1

Recruiting

Conditions: Stage II Renal Cell Cancer
Stage I Renal Cell Cancer

Interventions: Procedure: Angiogram
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Radiation: Radioembolization
Procedure: Single Photon Emission Computed Tomography
Other: Survey Administration
Radiation: Yttrium Y 90 Glass Microspheres

First Posted Date: 2024-05-29

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT06432036

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer

Active, not recruiting

Conditions: Early Stage Breast Carcinoma

Interventions: Other: Non-Interventional Study

First Posted Date: 2024-04-26

Last Posted Date: 2025-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 2

Registration Number: NCT06387173

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Improving Colonoscopy Surveillance for Patients with High Risk Colon Polyps

Not Applicable

Recruiting

Conditions: Colorectal Carcinoma

Interventions: Other: Interview
Other: Communication Intervention
Other: Best Practice

First Posted Date: 2024-04-19

Last Posted Date: 2024-10-30

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1680

Registration Number: NCT06376565

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Phase 1

Recruiting

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions: Procedure: Biospecimen Collection
Biological: Dendritic Cell Therapy
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Poly ICLC

First Posted Date: 2024-04-02

Last Posted Date: 2024-12-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT06342908

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Phase 2

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Gallium Ga 68 Gozetotide
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
Procedure: Positron Emission Tomography
Other: Questionnaire Administration
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2024-03-01

Last Posted Date: 2024-08-07

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT06288113

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

Phase 1

Recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Fluoxetine

First Posted Date: 2024-01-25

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT06225011

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Phase 2

Recruiting

Conditions: Prostate Carcinoma
Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

Interventions: Procedure: Computed Tomography
Other: Gallium Ga 68 Gozetotide
Drug: Lutetium Lu 177 Vipivotide Tetraxetan
Procedure: Positron Emission Tomography
Procedure: PSMA PET Scan
Other: Questionnaire Administration
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2024-01-22

Last Posted Date: 2025-02-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 90

Registration Number: NCT06216249

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
Early Stage Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Educational Intervention
Other: Exercise Intervention
Drug: Fisetin
Other: Physical Performance Testing
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2023-11-02

Last Posted Date: 2024-12-20

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 164

Registration Number: NCT06113016

Locations: 🇺🇸
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
🇺🇸
UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States
🇺🇸
UCLA Health Burbank Primary & Specialty Care, Burbank, California, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy